Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
$0.25
$0.01(1.52%)
At close: 4:00 PM EST
$0.25
$0.01(1.52%)
Day’s Range― - ―
52-Week Range$0.22 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)2.65M
Market Cap
$30.70M
Enterprise Value$83.20M
Total Cash (Recent Filing)$199.41K
Total Debt (Recent Filing)$11.26M
Price to Earnings (P/E)―
Beta0.45
Next Earnings
Mar 31, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding122,801,575
10 Day Avg. Volume2,450,486
30 Day Avg. Volume2,654,041
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-2.08
Price to Sales (P/S)42.09
P/FCF Ratio-1.96
Enterprise Value/Market Cap2.71
Enterprise Value/Revenue56.52
Enterprise Value/Gross Profit56.52
Enterprise Value/Ebitda-4.11
Forecast
1Y Price Target
$2.25Price Target Upside800.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product DevelopmentVolition continues to develop its Nu.Q Vet business and is working on partnerships and licensing for its Nu.Q Netosis and Oncology programs, which could become significant revenue sources.
Revenue GrowthRevenue grew 32%; more licensing deals expected.
Strategic PartnershipsThe company entered two human diagnostics agreements, including a research license and exclusive commercial option rights agreement for Antiphospholipid Syndrome with Werfen and a co-marketing and services agreement with Hologic.
Bears Say
Earnings Performance3Q25 fully adjusted EPS of ($0.05) missed consensus of ($0.04).
Financial ChallengesConcerns exist regarding the company's balance sheet, with Volition having a low cash position and high burn rate, indicating a need for additional capital soon.
Revenue ConsistencyRevenue is expected to remain inconsistent, and there is high uncertainty about partnership strategies, particularly regarding timing and deal structure.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.22 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $30.70M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Mar 31, 2026 which is in 91 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Nov 13, 2025. The company reported -$0.05 earnings per share for the quarter, missing the consensus estimate of -$0.044 by -$0.006.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.05.
How many shares outstanding does VolitionRX have?
VolitionRX has 122,801,575 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.05 in its last earnings report, missing expectations of -$0.044. Following the earnings report the stock price went down -5.714%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
VolitionRX Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.25 (800.00% Upside)
$2.25 (800.00% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $136.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.2%
Last 30 Days ▲ 25.5%
Last 30 Days ▲ 25.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-49.14%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in revenue growth, cost management, and strategic partnerships with major companies like Werfen and Hologic. Scientific advancements also promise future potential. However, challenges remain, such as unpredictable revenue and uncertainty in closing additional licensing agreements.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.25
▲(800.00% Upside)
Technical Analysis
Ownership Overview
10.40% Insiders
1.37% Mutual Funds
18.04% Other Institutional Investors
69.36% Public Companies and
Individual Investors